BioPharma Dive June 13, 2024
The results support a key component of a combination vaccine the company has said it aims to bring to market next year.
Dive Brief:
- Moderna said its next-generation COVID-19 vaccine succeeded in a Phase 3 study, offering increased effectiveness for adults.
- The vaccine, known as mRNA-1283, is designed to fight newer strains of coronavirus that have emerged since the development of Moderna’s original shot, Spikevax. Overall, the trial found the new version works at least as well as the old one, but its effects were even stronger in patients who were at least 18 years old, the company said Thursday.
- Executives will consult with regulators on next steps for the vaccine, Moderna said. Results from the Phase 3 trial,...
Today's Sponsors
Today's Sponsor